Guardant Health Inc. announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025. For the fourth quarter of 2025, the company reported total revenue of approximately $280 million, representing a 39% increase compared to the same period in 2024. Oncology test volumes reached approximately 79,000, an increase of 38%, while Shield screening tests totaled about 38,000, up from 6,400 in the prior year period. For the full year 2025, Guardant Health reported approximately 276,000 oncology tests, a 34% increase year-over-year, and around 87,000 Shield screening tests. The company stated that total revenue growth for 2025 accelerated to 33% compared to the previous year. Guardant Health noted that these results are preliminary and unaudited, and final audited results are expected to be reported during the company’s February 2026 earnings call.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001576280-26-000004), on January 12, 2026, and is solely responsible for the information contained therein.